NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03734029,Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04],https://clinicaltrials.gov/study/NCT03734029,,ACTIVE_NOT_RECRUITING,"This study will compare DS-8201a to physician choice standard treatment.

Participants must have HER2-low breast cancer that has been treated before.

Participants' cancer:

* Cannot be removed by an operation
* Has spread to other parts of the body",YES,Breast Cancer,DRUG: Trastuzumab deruxtecan (DS-8201a)|DRUG: Capecitabine|DRUG: Eribulin|DRUG: Gemcitabine|DRUG: Paclitaxel|DRUG: Nab-paclitaxel,"Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer, Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on blinded independent central review (BICR) in the hormone receptor-positive cohort according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method., From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years","Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-low Breast Cancer (All Patients) Regardless of Hormone Receptor Status, Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on blinded independent central review (BICR) according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method., From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years|Progression-free Survival Based on Investigator Assessment in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer, Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on investigator assessment in the hormone receptor-positive cohort according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method., From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years|Progression-free Survival Based on Investigator Assessment in Participants With HER2-low Breast Cancer (All Patients), Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on investigator assessment according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method., From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years|Overall Survival (OS) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer, Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there was no death reported for a participant before the data cutoff for OS analysis, OS was censored at the last contact date at which the participant was known to be alive., From the date of randomization up to the date of death due to any cause, up to approximately 3 years|Number of Overall Survival Events (Deaths), From the date of randomization up to the date of death due to any cause, up to approximately 3 years|Overall Survival (OS) in All Patients, Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there was no death reported for a participant before the data cutoff for OS analysis, OS was censored at the last contact date at which the participant was known to be alive., From the date of randomization up to the date of death due to any cause, up to approximately 3 years|Best Overall Response and Confirmed Objective Response Rate (ORR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer, Best overall response rate and confirmed objective response rate (ORR) were assessed by blinded independent central review (BICR) and investigator assessment. Complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. Confirmed ORR was defined as the number of participants with complete and partial responses and confirmed by a second assessment., From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years|Best Overall Response and Confirmed Objective Response Rate (ORR) in Participants With HER2-low Breast Cancer (All Patients), Best overall response rate and confirmed objective response rate (ORR) were assessed by blinded independent central review (BICR) and investigator assessment. Complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. Confirmed ORR was defined as the number of participants with complete and partial responses and confirmed by a second assessment., From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years|Duration of Response in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer, Duration of Response (DoR) is defined as the date of the first documented objective response (complete response \[CR\] or partial response \[PR\]) to the first documented disease progression or death, whichever occurs first. DoR was based on blinded independent central review (BICR) and investigator assessment. Median was from Kaplan-Meier estimate. Confidence interval for median was computed using the Brookmeyer-Crowley method., From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years|Duration of Response in Participants With HER2-low Breast Cancer (All Patients), Duration of Response (DoR) is defined as the date of the first documented objective response (complete response \[CR\] or partial response \[PR\]) to the first documented disease progression or death, whichever occurs first. DoR was based on blinded independent central review (BICR) and investigator assessment. Median was from Kaplan-Meier estimate. Confidence interval for median was computed using the Brookmeyer-Crowley method., From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years","All-Cause Mortality, All-cause mortality is defined as all anticipated and unanticipated deaths due to any cause, with the number and frequency of such events by arm or comparison group of the clinical study., From the date of randomization up to the date of death due to any cause, up to approximately 3 years",Daiichi Sankyo,"Daiichi Sankyo Co., Ltd.|AstraZeneca",ALL,"ADULT, OLDER_ADULT",PHASE3,557,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,DS8201-A-U303|2018-003069-33|184223|DESTINY-B04,2018-12-27,2022-01-11,2025-10-01,2018-11-07,2023-06-15,2024-04-11,"Ironwood Cancer & Research Centers - Chandler II, Chandler, Arizona, 85224, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, 85234-2165, United States|Cancer Treatment Centers of America at Western Regional Medical Center, Goodyear, Arizona, 85338, United States|UCLA School of Medicine, Los Angeles, California, 90095-1690, United States|Stanford Cancer Institute, Palo Alto, California, 94305, United States|Cancer Care Associates Medical Group, Inc. TORI, Redondo Beach, California, 90277, United States|University of California at San Francisco (PARENT), San Francisco, California, 94158, United States|Eastern Connecticut Hematology/Oncology Assoc., Norwich, Connecticut, 06360, United States|Christiana Care Health Services, Inc., Newark, Delaware, 19713, United States|Sylvester Comprehensive Cancer Center - Deerfield Beach, Boca Raton, Florida, 33426, United States|Florida Cancer Specialists (South Region), Fort Myers, Florida, 33916, United States|Memorial Healthcare System MRH Cancer Center, Hollywood, Florida, 33021, United States|Orlando Health, Inc., Orlando, Florida, 32806, United States|Moffitt Cancer Center -Tampa, Tampa, Florida, 33139, United States|Cancer Treatment Centers of America-Georgia, Newnan, Georgia, 30263, United States|University of Chicago Medical Center, Chicago, Illinois, 60637, United States|Cancer Treatment Centers of America, Zion, Illinois, 60099, United States|Cancer Center of Kansas, Wichita, Kansas, 67214, United States|Touro Infirmary, New Orleans, Louisiana, 70115, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Henry Ford Hospital, Detroit, Michigan, 48202, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, 64111, United States|Saint Barnabas Medical Center, Livingston, New Jersey, 07039, United States|New York University Medical Center, New York, New York, 10016, United States|Memorial Sloan Kettering Hospital, New York, New York, 10065-6007, United States|Weill Cornell Medicine Breast Center, New York, New York, 10065, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|Oregon Health & Science University, Portland, Oregon, 97239, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, 15212, United States|University of Pittsburgh Medical Center Health System, Pittsburgh, Pennsylvania, 15219, United States|St Francis Hospital, Greenville, South Carolina, 29601, United States|Brig Center for Cancer Care and Survivorship, Knoxville, Tennessee, 37909, United States|Baptist Cancer Center, Memphis, Tennessee, 38120, United States|Tennessee Oncology - Skyline Satellite, Nashville, Tennessee, 37201, United States|BloomTrials Clinical Research, LLC, Dallas, Texas, 75234, United States|The Methodist Hospital Research Institute, Houston, Texas, 77030, United States|University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics, Houston, Texas, 77030, United States|Virginia Cancer Specialists, Fairfax, Virginia, 22031, United States|Medizinische Universität Innsbruck, Innsbruck, 6020, Austria|Kepler Universitätsklinikum, Linz, 4020, Austria|LKH - Universitätsklinikum der PMU Salzburg, Salzburg, 5020, Austria|AKH - Medizinische Universität Wien (4305), Vienna, 1090, Austria|Klinikum Wels-Grieskirchen GmbH, Wels, 4600, Austria|Institut Jules Bordet, Bruxelles, 1000, Belgium|Universitair Ziekenhuis Brussel, Bruxelles, 1090, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, 1200, Belgium|UZ Leuven, Leuven, 3000, Belgium|Grand Hôpital de Charleroi, Loverval, 6280, Belgium|CHU UCL Namur, Namur, 5000, Belgium|Centre Hospitalier Wallonie picarde - Site IMC, Tournai, 7500, Belgium|Tom Baker Cancer Center, Calgary, Alberta, T2N4N2, Canada|Toronto Sunnybrook Hospital, Toronto, Ontario, M4N 3M5, Canada|McGill University - Dept. Oncology Clinical Research Program, Montréal, Quebec, H2W 1S6, Canada|Anhui Provincial Hospital, Hefei, Anhui, 230001, China|Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, 100021, China|Chinese PLA General Hospital, Beijing, Beijing, 100853, China|Fuzhou General Hospital of Nanjing Military Area Command of Chinese PLA, Fuzhou, Fujian, 350025, China|Sun Yat-sen Memorial hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510120, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China|Hubei Cancer Hospital, Wuhan, Hubei, 430079, China|The Affiliated Drum Tower Hospital of Nanjing University, Nanjing, Jiangsu, 210008, China|The First Hospital of Jilin University, Chang chun, Jilin, 130000, China|Jilin Cancer Hospital, Chang chun, Jilin, 130012, China|Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, 110042, China|General Hospital of Ningxia Medical University, Yinchuan, Ningxia, 750004, China|Linyi Cancer Hospital, Linyi, Shandong, 276001, China|Shanghai General Hospital, Shanghai, Shanghai, 200080, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, 20032, China|West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China|Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, 310016, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310022, China|Institut Paoli Calmettes, Marseille cedex 9, Bouches-du-Rhône, 13009, France|Centre François Baclesse, Caen, Calvados, 14076, France|CARIO - Centre Armoricain de Radiothérapie, Imagerie médicale et Oncologie, Plérin, Cotes d'Armor, 22190, France|CHU Brest - Hôpital Morvan, Brest Cedex, Finistere, 29609, France|Institut Bergonié, Bordeaux cedex, Gironde, 33076, France|Clinique Clementville, Montpellier, Herault, 34070, France|Institut Régional du Cancer de Montpellier, Montpellier, Herault, 34298, France|CRLCC Eugene Marquis, Rennes-cedex, Ille Et Vilaine, 35042, France|ICO - Site René Gauducheau, Saint-Herblain, Loire Atlantique, 44805, France|Centre Hospitalier Emile Roux, Le Puy-en-Velay, Loiret, 43012, France|ICO - Site Paul Papin, Angers Cedex 2, Maine Et Loire, 49055, France|Centre Hospitalier Valenciennes, Valenciennes, Nord, 59322, France|Hôpital Saint-Louis - Paris, Paris Cedex 10, Paris, 75475, France|Clinique Victor Hugo - Centre Jean Bernard, Le Mans Cedex 02, Sarthe, 72015, France|Institut Sainte Catherine, Avignon Cedex 9, Vaculuse, 84918, France|Hôpital d'Instruction des Armees Begin*, Saint Mande, Val De Marne, 94160, France|Institut Gustave Roussy, Villejuif cedex, Val De Marne, 94805, France|Institut Curie - site de Paris, Paris, 75005, France|Hopital Tenon, Paris, 75020, France|Universitaetsklinikum Heidelberg, Heidelberg, Baden Wuerttemberg, 69120, Germany|Klinikum der Universitaet Muenchen - Campus Grosshardern, Munich, Bayern, 81377, Germany|General Hospital of Athens ""Alexandra"", Athens, 11528, Greece|General Oncology Hospital of Kifissia "" Agioi Anargyroi"", Athens, 14564, Greece|Athens Medical Center, Athens, 15125, Greece|University General Hospital of Heraklion, Heraklion, 71110, Greece|University General Hospital of Larissa, Larissa, 41110, Greece|Bioclinic Thessaloniki, Thessaloníki, 54622, Greece|Euromedica General Clinic Thessaloniki, Thessaloníki, 54645, Greece|General Hospital Papageorgiou, Thessaloníki, 56429, Greece|Interbalkan Hospital of Thessaloniki, Thessaloníki, 57001, Greece|Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet, Budapest, 1097, Hungary|Orszagos Onkologiai Intezet, Budapest, 1122, Hungary|Debreceni Egyetem, Debrecen, 4032, Hungary|Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza, Gyula, 5700, Hungary|SzSzB Megyei Korhazak es Egyetemi Oktatokorhaz, Nyiregyhaza, 4400, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet, Szolnok, 5004, Hungary|Rambam Health Care Center, Haifa, 3109601, Israel|Shaare Zedek Medical Center, Jerusalem, 9103102, Israel|Hadassah University Hospital - Ein Kerem, Jerusalem, 9112001, Israel|Rabin Medical Center-Beilinson Campus, Petah tikva, 49100, Israel|Chaim Sheba Medical Center, Ramat Gan, 52363, Israel|Kaplan Medical Center, Rechovot, 7610001, Israel|Ziv Medical Center, Safed, 13100, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, 6423906, Israel|Azienda Ospedaliera Card. G. Panico, Tricase, Lecce, 73039, Italy|Azienda Socio Sanitaria Territoriale di Monza (Presidio San Gerardo), Monza, Milano, 20900, Italy|Istituto Clinico Humanitas, Rozzano, Milano, 20089, Italy|Ospedale Sacro Cuore Don Calabria, Negrar, Verona, 37024, Italy|Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi, Bologna, 40138, Italy|Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili), Brescia, 25100, Italy|Azienda Ospedaliera Univ. Policlinico Gaspare Rodolico, Catania, 95125, Italy|Azienda Ospedaliero Universitaria Mater Domini-Campus Universitario, Catanzaro, 88100, Italy|IEO Istituto Europeo di Oncologia, Milano, 20141, Italy|Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, 80131, Italy|Ospedale degli Infermi, Rimini, 47923, Italy|Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Roma, 00133, Italy|Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, 00168, Italy|Aichi Cancer Center Hospital, Nagoya, Aichi-Ken, 464-8681, Japan|National Cancer Center Hospital East, Kashiwa-shi, Chiba-Ken, 277-8577, Japan|NHO Shikoku Cancer Center, Matsuyama-shi, Ehime-Ken, 791-0280, Japan|NHO Kyushu Cancer Center, Fukuoka-shi, Fukuoka-Ken, 811-1395, Japan|Fukushima Medical University Hospital, Fukushima, Fukushima-Ken, 960-1295, Japan|Hiroshima City Hiroshima Citizens Hospital, Hiroshima-shi, Hiroshima-Ken, 730-8518, Japan|NHO Hokkaido Cancer Center, Sapporo-shi, Hokkaido, 003-0804, Japan|Hyogo College of Medicine Hospital, Nishinomiya-shi, Hyogo-Ken, 663-8501, Japan|Hakuaikai Sagara Hospital, Kagoshima, Kagoshima-Ken, 892-0833, Japan|Tokai University Hospital, Isehara, Kanagawa-Ken, 259-1193, Japan|Kanagawa Cancer Center, Yokohama, Kanagawa, 241-8515, Japan|NHO Osaka National Hospital, Osaka-shi, Osaka-Fu, 540-0006, Japan|Kindai University Hospital, Onohigashi, Osakasayama-shi, 589-8511, Japan|Saitama Cancer Center, Kitaadachi-gun, Saitama-Ken, 362-0806, Japan|Shizuoka Cancer Center, Sunto-gun, Shizuoka-Ken, 411-8777, Japan|Cancer Institute Hospital of JFCR, Koto-Ku, Tokyo-To, 135-8550, Japan|Toranomon Hospital, Minato-Ku, Tokyo-To, 105-8470, Japan|Showa University Hospital, Shinagawa-Ku, Tokyo-To, 142-8666, Japan|Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do, 361-711, Korea, Republic of|National Cancer Center, Goyang-si, Gyeonggi-do, 10408, Korea, Republic of|Inha University Hospital, Incheon, Gyeonggi-do, 22332, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, 13620, Korea, Republic of|Ajou University Hospital, Suwon, Gyeonggi-do, 16499, Korea, Republic of|Kyungpook National University Chilgok Hospital, Daegu, 41404, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, 06591, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, 120-752, Korea, Republic of|Hospital de Braga, Braga, 4710-243, Portugal|Centro Hospitalar do Alto do Ave, EPE, Guimarães, 4835-044, Portugal|Fundação Champalimaud, Lisboa, 1400-038, Portugal|Centro Hospitalar de Lisboa Norte, E.P.E. - Hospital de Santa Maria, Lisboa, 1649-035, Portugal|Unidade Local de Saúde de Matosinhos, EPE (Hospital Pedro Hispano), Matosinhos, 4464-509, Portugal|Centro Hospitalar do Porto, E.P.E. - Hospital de Santo António, Porto, 4099-001, Portugal|Instituto Português de Oncologia do Porto Francisco Gentil, EPE, Porto, 4200-072, Portugal|Centro Hospitalar de Entre o Douro e Vouga, E.P.E - Hospital de São Sebastião, Santa Maria Da Feira, 4520-211, Portugal|Centro Hospitalar Vila Nova de Gaia/Espinho, E.P.E, Vila Nova De Gaia, 4434-502, Portugal|Centro Hospitalar de Trás-os-Montes e Alto Douro, EPE, Vila Real, 5000-508, Portugal|FSBSI ""Russian Oncological Scientific Center n.a. N.N. Blokhin"", Moscow, 115478, Russian Federation|SBIH of Moscow City ""Moscow City Oncology Hospital №62"" of Moscow Healthcare Departement, Moscow, 143423, Russian Federation|SBIH of Yaroslavl Region ""Regional Clinical Oncological Hospital"", Yaroslavl, 150054, Russian Federation|ICO l'Hospitalet - Hospital Duran i Reynals, L'Hospitalet De Llobregat, Barcelona, 08908, Spain|Hospital Universitario Donostia, San Sebastián, Guipuzcoa, 20014, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, La Coruña, 15006, Spain|Hospital Universitario de Canarias, San Cristobal de la Laguna, Tenerife, 38320, Spain|Hospital de Basurto, Bilbao, Vizcaya, 48013, Spain|Hospital del Mar, Barcelona, 08003, Spain|Hospital Quironsalud Barcelona, Barcelona, 08023, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital Clinic de Barcelona, Barcelona, 08036, Spain|MD Anderson Cancer Centre, Madrid, 28033, Spain|Hospital Ruber Internacional, Madrid, 28034, Spain|Hospital Universitario Ramon y Cajal, Madrid, 28034, Spain|Hospital Universitario Clinico San Carlos, Madrid, 28040, Spain|Hospital Clinico Universitario Virgen de la Victoria, Málaga, 29010, Spain|Hospital Universitario Virgen Macarena, Sevilla, 41009, Spain|Hospital Universitario Virgen del Rocio, Sevilla, 41013, Spain|Instituto Valenciano de Oncologia IVO, Valencia, 46009, Spain|Hospital General Universitario de Valencia, Valencia, 46014, Spain|Karolinska universitetssjukhuset - Solna, Solna, 17176, Sweden|Länssjukhuset Sundsvall-Härnösand, Sundsvall, 85186, Sweden|Akademiska Sjukhuset, Uppsala, 75185, Sweden|Hirslanden Medical Center, Aarau, 5000, Switzerland|Universitaetsspital Basel, Basel, 4031, Switzerland|Kantonsspital Graubuenden, Chur, 7000, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, 1011, Switzerland|Kantonsspital St. Gallen, Saint Gallen, 9007, Switzerland|Kantonsspital Winterthur, Winterthur, 8401, Switzerland|Universitaetsspital Zuerich, Zürich, 8091, Switzerland|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, 807, Taiwan|National Cheng Kung University Hospital, Tainan, 704, Taiwan|National Taiwan University Hospital, Taipei, 100, Taiwan|Royal Cornwall Hospital, Truro, Cornwall, TR1 3LJ, United Kingdom|Queen Mary University of London, London, Greater London, EC1M 6BQ, United Kingdom|University College London Hospitals, London, Greater London, NW1 2PG, United Kingdom|Royal Free Hospital, London, Greater London, NW3 2QG, United Kingdom|Western General Hospital, Edinburgh, Lothian Region, EH4 2XU, United Kingdom|Nottingham University Hospitals City Campus, Nottingham, Nottinghamshire, NG5 1PB, United Kingdom|Royal Surrey County Hospital, Guildford, Surrey, GU2 7XX, United Kingdom","Study Protocol and Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/29/NCT03734029/Prot_SAP_000.pdf"
